TY - JOUR
T1 - Cell-based assays and molecular dynamics analysis of a boron-containing agonist with different profiles of binding to human and guinea pig beta2 adrenoceptors
AU - Soriano-Ursúa, Marvin A.
AU - Bello, Martiniano
AU - Hernández-Martínez, Christian F.
AU - Santillán-Torres, Iván
AU - Guerrero-Ramírez, Ruth
AU - Correa-Basurto, José
AU - Arias-Montaño, José Antonio
AU - Trujillo-Ferrara, José G.
N1 - Publisher Copyright:
© 2018, European Biophysical Societies' Association.
PY - 2019/1/15
Y1 - 2019/1/15
N2 - The design of beta2 adrenoceptor (β 2 AR) agonists is attractive because of their wide-ranging applications in medicine, and the details of agonist interactions with β 2 AR are interesting because it is considered a prototype for G-protein coupled receptors. Preclinical studies for agonist development have involved biological assays with guinea pigs due to a similar physiology to humans. Boron-containing Albuterol derivatives (BCADs) designed as bronchodilators have improved potency and efficacy compared with their boron-free precursor on guinea pig β 2 ARs (gpβ 2 ARs), and two of the BCADs (BR-AEA and boronterol) conserve these features on cells expressing human β 2 ARs (hβ 2 ARs). The aim of this study was to test the BCAD Politerol on gpβ 2 ARs and hβ 2 ARs in vitro and in silico. Politerol displayed higher potency and efficacy on gpβ 2 AR than on hβ 2 AR in experimental assays, possible explanations are provided based on molecular modeling, and molecular dynamics simulations of about 0.25 µs were performed for the free and bound states adding up to 2 µs in total. There were slight differences, particularly in the role of the boron atom, in the interactions of Politerol with gpβ 2 ARs and hβ 2 ARs, affecting movements of transmembrane domains 5–7, known to be pivotal in receptor activation. These findings could be instrumental in the design of compounds selective for hβ 2 ARs.
AB - The design of beta2 adrenoceptor (β 2 AR) agonists is attractive because of their wide-ranging applications in medicine, and the details of agonist interactions with β 2 AR are interesting because it is considered a prototype for G-protein coupled receptors. Preclinical studies for agonist development have involved biological assays with guinea pigs due to a similar physiology to humans. Boron-containing Albuterol derivatives (BCADs) designed as bronchodilators have improved potency and efficacy compared with their boron-free precursor on guinea pig β 2 ARs (gpβ 2 ARs), and two of the BCADs (BR-AEA and boronterol) conserve these features on cells expressing human β 2 ARs (hβ 2 ARs). The aim of this study was to test the BCAD Politerol on gpβ 2 ARs and hβ 2 ARs in vitro and in silico. Politerol displayed higher potency and efficacy on gpβ 2 AR than on hβ 2 AR in experimental assays, possible explanations are provided based on molecular modeling, and molecular dynamics simulations of about 0.25 µs were performed for the free and bound states adding up to 2 µs in total. There were slight differences, particularly in the role of the boron atom, in the interactions of Politerol with gpβ 2 ARs and hβ 2 ARs, affecting movements of transmembrane domains 5–7, known to be pivotal in receptor activation. These findings could be instrumental in the design of compounds selective for hβ 2 ARs.
KW - Adrenoceptor
KW - Boron
KW - Cell-based assays
KW - Comparative physiology
KW - GPCR
KW - Pharmacology
UR - http://www.scopus.com/inward/record.url?scp=85055972597&partnerID=8YFLogxK
U2 - 10.1007/s00249-018-1336-9
DO - 10.1007/s00249-018-1336-9
M3 - Artículo
C2 - 30386878
SN - 0175-7571
VL - 48
SP - 83
EP - 97
JO - European Biophysics Journal
JF - European Biophysics Journal
IS - 1
ER -